[Home ] [Archive]   [ فارسی ]  
:: Main :: About us :: Current Issue :: Archive :: Search :: Submit :: Contact ::
Main Menu
Home::
Journal Information::
About the Journal
Editorial Board
Advisory Board
Aims & Scope
Journal News
Articles archive::
All Issues
Current Issue
Articles in press
For Authors::
Submission Instruction
For Reviewers::
Reviewers Section
Subscription::
Subscription Form
News& Events::
Journal News
Contact us::
Contact Information
Contact us
Site Facilities::
Site map
Search contents
Top 10 contents
Inform others
Ethics & Permissions::
::
Search in website

Advanced Search
..
Receive site information
Enter your Email in the following box to receive the site news and information.
..
Indexing
                        
..
:: Volume 13, Issue 2 (Summer 2016) ::
Sci J Iran Blood Transfus Organ 2016, 13(2): 146-155 Back to browse issues page
Evaluation of the incidence of splenectomy and frequency of regular iron chelation therapy in patients with thalassemia Major in Iran: a meta-analysis
M. Azami , S. Nikpay , Gh. Abangah , K. Sayehmiri
Keywords: Key words: Splenectomy, Chelation Therapy, Blood Transfusion, beta-Thalassemia, Iran, Meta-Analysis
Full-Text [PDF 377 kb]   (1434 Downloads)     |   Abstract (HTML)  (6242 Views)
Type of Study: Review Article | Subject: Epidemiolgy & Statistical
Published: 2016/06/15
Full-Text:   (2009 Views)
References :  
  1. Modell B, Darlison M. Global epidemiology of haemoglobin disorders and derived service indicators. Bull World Health Organ 2008; 86(6): 480-7.
  2. De Sanctis V. Growth and puberty and its management in thalassaemia.Horm Res 2002; 58(1):72-9.
  3. De Sanctis V, Tangerini A, Testa MR, Lauriola AL, Gamberini MR, Cavallini AR, et al. Final height and endocrine function in thalassaemia intermedia.J Pediatr Endocrinol Metab 1998; 11(3): 965-71.
  4. Raiola G, Galati MC, De Sanctis V, Caruso Nicoletti M, Pintor C, De SimoneM, et al. Growth and puberty in thalassemia major.J Pediatr Endocrinol Metab 2003; 16(2): 259-66.
  5. Al-Elq AH, Al-Saeed HH. Endocrinopathies in patients with thalassemias. Saudi Med J 2004; 25(10): 1347-51.
  6. Azizi F, Hatami H, Janghorbani M. Epidemiology and controlling prevalent disease in Iran. 1st ed. Tehran: Eshtiagh Publication; 1994. p.52. [Persian]
  7. Crary SE, Buchanan GR. Vascular complications after splenectomy for hematologic disorders. Blood 2009; 114(14): 2861-8.
  8. Madan N, Sharma S, Sood SK, Colah R, Bhatia LH. Frequency of ß-thalassemia trait and other hemoglobinopathies in northern and western India. Indian J Hum Genet 2010; 16(1): 16-25.
  9. Goldman L, Bennett JC. Cecil Textbook of Medicine. 21st ed. Philadelphia: Saunders; 2000. p. 884-9.
  10. Talaeizadeh AH, Askarpoor B, Zandian KM. Outcomes of splenectomy in thalassemic patients. Sci Med J Ahwaz Univ Med Sci 2004; 40: 31-8. [Article in Farsi]
  11. Cappellini MD, Cohen A, Porter J, Taher A, Viprakasit V. Guidelines for the management of transfusion dependent thalassaemia (TDT). 3rd ed. Nicosia: Thalassaemia International Federation; 2014. p. 126-33.
  12. Piga A, Serra M, Longo F, Forni G, Quarta G, Cappellini MD, et al. Changing patterns of splenectomy in transfusion-dependent thalassemia patients. Am J Hematol 2011; 86(9): 808-10.
  13. Das A, Bansal D, Das R, Trehan A, Marwaha RK. Hereditary spherocytosis in children: profile and post-splenectomy outcome. Indian Pediatr 2014; 51(2): 139-41.
  14. Aydinok Y, Bayraktaroglu S, Yildiz D, Alper H. Myocardial iron loading in patients with thalassemia major in Turkey and the potential role of splenectomy in myocardial siderosis. J Pediatr Hematol Oncol 2011; 33(5): 374-8.
  15. Bhatia M, Cairo MS. Splenectomy or no splenectomy prior to allogeneic stem-cell transplantation in patients with severe thalassemia: this is the question. Pediatr Transplant 2009; 13(2): 143-5.
  16. Cooper MJ, Williamson RC. Splenectomy: indications, hazards and alternatives. Br J Surg 1984; 71(3): 173-80.
  17. Elison E, Fabri P. Complications of splenectomy: etiology, prevention, and management. Surg Clin North Am 1983; 63(6): 1313-30.
  18. Bisharat N, Omari H, Lavi I, Raz R. Risk of infection and  death  among  post-splenectomy  patients.  J Infect
 
2001; 43(3): 182-6.
  1. Ansari H, Parisay Z, Tabatabaee S, Rakhshani F, Zare N. The assessment of Hypogonadism Occurence and Related Factors among Beta Thalassemia Major Patients using Survival Analysis model. Horizon Med Sci 2008; 14(1): 5-12
  2. Mehrvar A, Azarkeivan A, Saberi Nejad J, Mehran N, Faranoosh M, Vosoogh P. Prevalence of hypothyroidism and hypoparathyroidism in patients with ß thalassemia in Iran. Sci J Iran Blood Transfus Organ 2008; 5(1): 53-9. [Article in Farsi]
  3. Zendeyad A, Myrbhbahany N.b. Assessment of the relationship between hypothyroidism and serum ferritin in patients with β-thalassemia. Medical Journal of Mashad University of Medical Sciences 2009; 52(3): 123-8. [Article in Farsi]
  4. Company F, Rezaie R, Yosefi GH. Evaluation of hearing loss and otolaryngeal disorders in beta thalassemic patients treated with desferrioxamine. Scientific Journal of Kurdistan University of Medical Sciences 2009; 14(3): 47-55. [Article in Farsi]
  5. Azimipour A, Asadi M. The prevalence of endocrine diseases in patients with thalassemia major [Dissertation]. Qazvin: Qazvin University of Medical Sciences; 2001. p. 17.
  6. Alavi S, Arzanian M, Ahmadinejad M, Meshkat Razavi G, Valaee N, Tabatabaee M, et al . Natural anticoagulant system in children with beta-thalassemia major. Sci J Iran Blood Transfus Organ 2007; 4(3): 181-7. [Article in Farsi]
  7. Hiradfar AA, Keikhai B, Pedram M. Determination of Clinical Prevalence and Predominant Pattern of RBCs Alloimmunization among Transfusion Dependent Thalassemic Patients in Ahvaz. Sci Med J Ahwaz Univ Med Sci 2010; 9(68): 441-8.
  8. Company F, Zandian Kh, Pedram M, Shahbazian H, Rezaei N. Abnormal Glucose Tolerance and Diabetes Mellitus in β Thalassemic Patients with Transfusion Dependent at Ahwaz Thalassemia Research Center. Sci Med J Ahwaz Univ Med Sci 2007; 6(53): 199-209.
  9. Company F, Rezaei N, Pourmohmmad B, Gharibi F. Assessment of thyroid dysfunction in patients with β- thalassemia major. Scientific Journal of Kurdistan University of Medical Sciences 2009; 13(4): 37-44. [Article in Farsi]
  10. Ansari H, Tabatabae H. study of factors in major beta thalassemia complications in Patients admitted to Shahid Dastgheib hospital in Shiraz, Iran (2004-5). Medical Journal of Sabzevar University of Medical Sciences 2007; 14(1): 62-72. [Article in Farsi]
  11. Hashemipour M, Rad M, Ebrahimi Meimand S. Orofacial disformation in thalassemia patient’s refered to Kerman special disease center in 2007. Sci J Iran Blood Transfus Organ 2008; 5(3): 185-93. [Article in Farsi]
  12. Mohammadi R, Allahyari I, Mazaheri E, Seyed Javadi M, Arish G. Evaluation of Physical Growth of Patients with Thalassemia Major Based on NCHS Criteria 2011; 13(1): 13-6. [Article in Farsi]
  13. Izadyar M, Sedighipourand L, Jafarieh H, Fatahi F. Evaluation Of compliance To Iron Chelation Therapy With Defe-Roxamine In Patients With Major Thalassemia In Iran In 2004. Tehran Univ Med J 2006; 64(2): 180-8. [Article in Farsi]
  14. Iramloo B, Ansari G, Qoreishi S. An epidemiologic assessment on the oral manifestations of B thalasemia in-patients referred to oncology wards in Tehran during 2000-2001. Beheshti Univ Dent J 2005; 22(Special Issue): 45-50.
  15. Tafazzoli Shadpour H. Evaluation of oralmanifestation and bonelesion in patient with major thalassemia (Qazvin, 1998-99). The Journal of Qazvin Univ of Med Sci 2003; 27: 48-53. [Article in Farsi]
  16. Babaee N, Tohidast Z., Nematzadeh F. Oral Manifestation and Complication in Patients with Thalassemia Major. Daneshvar Medicine 2008; 15(75): 1-8. [Article in Farsi]
  17. Hashemizadeh H, Noori R. Assessment of physical growth in patients with beta thalassemia major in Mashhad. Sci J Iran Blood Transfus Organ 2013; 9(4): 446-54. [Article in Farsi]
  18. Jalali Farahani F, Zolgaghari S, Talebian A, Azarkeivan A, Maghsudlu M, Sarmadi M, et al. Prevalence of thyroid dysfunction and relevant risk factors among thalassmia patients having referred to Iranian Blood Transfusion Organization Clinical Laboratory of Tehran. Sci J Iran Blood Transfus Organ 2009; 6(1): 59-64. [Article in Farsi]
  19. Azarkeivan A, Hajibeigy B, Afradi H, Eslami M, Ghazizadeh S, Shabeh Pour Z. Evaluation of clinical conditions of thalassemic patients having referred to Adult Thalassemia Center, Tehran. Sci J Iran Blood Transfus Organ 2011; 8(1): 32-41. [Article in Farsi]
  20. Rostami P, Hatami G, Shirkani A. Endocrine complications in patients with major β-thalassemia. Iranian South Medical Journal 2011; 14(4): 240-5.
  21. Zandian Kh, Eshagh Hossaini K, Riahi K. A study of prevalence of hypothyroidism in β-thalassemia major in Ahvaz Shafa hospital. Sci Med J 2009; 8(3): 289-94.
    [Article in Farsi]
  22. Vandenbroucke JP, Elm Ev, Altman DG, Gøtzsche PC, Mulrow CD, Pocock SJ, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. Epidemiology 2007; 18(6): 805-35.
  23. Aessopos A, Farmakis D, Hatziliami A, Fragodimitri C, Karabatsos F, Joussef J, et al. Cardiac status in well-treated patients with thalassemia major. Eur J Haematol 2004; 73(5): 359-66.
  24. Hagar RW, Morris CR, Vichinsky EP. Pulmonary hypertension in thalassaemia major patients with normal left ventricular systolic function. Br J Haematol 2006; 133(4): 433-5.
  25. Wu KH, Chang JS, Su BH, Peng CT. Tricuspid regurgitation in patients with beta-thalassemia major. Ann Hematol 2004; 83(12): 779-83.
  26. Al Hawsawi Zm, Hummalida TI, Ismail GA. Splenectomy in thalassemia major. Ann Trop Pediatr 2001; 21(2): 155-8.
  27. Taniguchi LU, Correia MD, Zampieri FG. Overwhelming post-splenectomy infection: narrative review of the literature. Surg Infect (Larchmt) 2014; 15(6): 686-93.
  28. Pouraboli B, Mansooreh Forouzi A, Arab M. Mental Health of Adolescents with Thalassemia Major Visiting Kerman Specific Diseases Center. Journal of Health & Development 2015; 4(1): 320-8.
  29. Azami M, Tardeh Z, Abangah GH, Sayehmiri K. The prevalence of impaired glucose tolerance in patients with thalassemia major - a systematic review and meta-analysis study. J Shahid Sadoughi Univ Med Sci 2016; 23(10): 912-22. [Article in Farsi]
  30. Azami M, Gheisoori A, Sayehmiri F, Sayehmiri K. Prevalence of hypothyroidism in patients with Beta thalassemia major in Iran: A systematic review and meta-analysis. J Kurdistan Uni Med Sci 2016; 22: 104-16. [Article in Farsi]
 
 
 
 
 
 
 


 
Review  Article
 

 
 
 
Sci J Iran Blood Transfus Organ 2016; 13(2): 146-155
 
Evaluation of the incidence of splenectomy
 and frequency of regular  iron chelation therapy in patients
with thalassemia Major in Iran: a meta-analysis
 
Azami M.1, Nikpay S.1, Abangah Gh.2, Sayehmiri K.3
 
 
1Student Research Committee, Ilam University of Medical Sciences, Ilam, Iran
2Faculty of Medicine, Ilam University of Medical Sciences, Ilam, Iran
3Research Center for Prevention of Psychosocial Medical Impairment, Ilam University of Medical Sciences , Ilam, Iran
 
Abstract
Background and Objectives
Splenectomy creates complications such as sepsis, thrombosis, pulmonary hypertension, altered immune status in patients with thalassemia major. These patients undergo hemochromatosis complications with non-normative treatment. This study aims at determining the incidence of splenectomy, the average age of onset of blood transfusions and frequency of regular iron chelation therapy in patients with thalassemia Major in Iran conducted through Meta-Analysis method.
 
Materials and Methods
This study is based on documentations obtained from the databases including Magiran, Iran medex, IranDoc, SID, Medlib, Embase, Scopus, Web of Science, Pubmed, ScienceDirect and Google Scholar from 1993 to 2015 and the standard keywords. Searches were independently carried out by two researchers. The data were combined using Random Effects Model through Meta-Analysis Method by Stata Ver.11.1 software.
 
Results
In 21 studies, 4017 samples were analyzed. The incidence of splenectomy in patients with thalassemia major was estimated to be 38.8% (CI 95%:31.4-46.2). The minimum and maximum of this range were related to the West (25%) and the East (44%) of the country. The average age of onset of blood transfusions and frequency of iron chelation therapy were estimated to be 11.86 months (CI 95%:7.86-16.05) and 54.6 % (CI 95%:28-81.2), respectively.
 
Conclusions
Given that a large percentage of patients with thalassemia major are treated with irregular iron chelation therapy, it is recommended measures such as training and awareness-raising activities to be taken for thalassemia patients.
 
Key words: Splenectomy, Chelation Therapy, Blood Transfusion, beta-Thalassemia, Iran, Meta-Analysis
 
 
 
Received:  23 Sep 2015
Accepted: 20 Dec 2015
 
 
 

Correspondence: Sayehmiri K., PhD in Biostatistics. Research Center for Prevention of Psychosocial Medical Impairment, Ilam University of Medical Sciences. Pazhuhesh Blv.
Postal Code: 6939177143, Ilam , Iran. Tel: (+9838) 316334; Fax: (+9838) 316334
E-mail:

 sayehmiri@razi.tums.ac.ir
Send email to the article author

Add your comments about this article
Your username or Email:

CAPTCHA

XML   Persian Abstract   Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Azami M, Nikpay S, Abangah G, Sayehmiri K. Evaluation of the incidence of splenectomy and frequency of regular iron chelation therapy in patients with thalassemia Major in Iran: a meta-analysis. Sci J Iran Blood Transfus Organ 2016; 13 (2) :146-155
URL: http://bloodjournal.ir/article-1-991-en.html
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 13, Issue 2 (Summer 2016) Back to browse issues page
فصلنامه پژوهشی خون Scientific Journal of Iran Blood Transfus Organ
The Scientific Journal of Iranian Blood Transfusion Organization - Copyright 2006 by IBTO
Persian site map - English site map - Created in 0.11 seconds with 39 queries by YEKTAWEB 4645